Spruce Biosciences financials
$47.27−0.51%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $4.9M | $10.1M | $0.00 | — | — |
| Gross profit | $0.00 | $4.9M | $10.1M | $0.00 | — | — |
| Gross margin | — | 100.0% | 100.0% | — | — | — |
| Operating income | -$36.5M | -$56.2M | -$52.0M | -$47.3M | -$42.1M | -$29.4M |
| Net income | -$39.0M | -$53.0M | -$47.9M | -$46.2M | -$42.3M | -$29.5M |
| Net margin | — | −1079.9% | −475.0% | — | — | — |
| Diluted EPS | $-50.83 | $-96.40 | $-93.00 | $-147.00 | $-135.75 | $-369.75 |
| EBITDA | -$36.5M | -$56.1M | -$51.9M | -$47.2M | -$42.1M | -$29.4M |
| Operating cash flow | -$33.3M | -$56.0M | -$33.3M | -$41.7M | -$35.9M | -$27.5M |
| Free cash flow | -$33.3M | -$56.0M | -$33.3M | -$41.7M | -$36.0M | -$27.6M |
| Diluted shares | 0.8M | 0.6M | 0.5M | 0.3M | 0.3M | 0.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $48.9M | $38.8M | $96.3M | $24.5M | $42.7M | $157.2M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $54.6M | $46.2M | — |
| Total debt | $0.00 | $1.7M | $3.3M | $4.9M | $4.9M | $4.5M |
| Total assets | $53.0M | $45.2M | $103.9M | $85.6M | $126.5M | $162.9M |
| Total liabilities | $10.5M | $16.4M | $27.4M | $17.2M | $15.1M | $13.5M |
| Shareholders' equity | $42.5M | $28.8M | $76.5M | $68.5M | $111.4M | $149.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology